Ypsomed Holding AG Overview
Pro stress-test →Ypsomed Holding AG develops, manufactures, and sells injection and infusion systems for safe and simple self-medication. The company operates across two primary business segments—Delivery Systems (serving pharmaceutical/biotech partners) and Diabetes Care (consumer/patient focused)—positioning itself as a critical infrastructure provider for the rapidly expanding injectable drug market, particularly in diabetes and GLP-1 therapies.
Strategic Profile
Pro stress-test →Ypsomed intends to focus on expanding its leading position in Delivery Systems and is examining strategic options for the Diabetes Care business area. The company is investing CHF 1.5 billion to nearly triple capacity to 1 billion devices by early next decade, with new sites in Germany, China, and the U.S. This aggressive expansion capitalizes on booming demand for autoinjectors as major pharma scales obesity and diabetes treatments.
Competitive Landscape
Pro stress-test →SHL Medical is a competitor of Ypsomed, a private equity-backed company in Zug, Switzerland. Other implicit competitors include larger medical device conglomerates and specialty pharma device partners like Gerresheimer and Schott Pharma. Ypsomed's competitive advantage stems from scale, integrated manufacturing footprint, and proven ability to customize for major pharma partners, creating high switching costs.
Industry Context
Ypsomed Holding AG operates in Medical Devices & Equipment - Injectable Drug Delivery Systems.
Key facts
Founded: 1984 · Headquarters: Burgdorf, Switzerland · Employees: 2644 · Revenue: $925M · Market cap: $5.76B